Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition

Lin, Yu Wei; Raj, Emmanuel Naveen; Liao, Wei; Lin, Johnson; Liu, Kuang Kai; Chen, Ting Hua; Cheng, Hsiao Chun; Wang, Chi Ching; Li, Lily Yi; Chen, Chinpiao; Ji, Chao

doi:10.1038/s41598-017-09983-8

Cited by 29 publications

(27 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surprisingly, ND-PTX-Cet significantly decreased tumor size in the xenograft model of EGFR-expressing human CRC tumors in nude mice. This study suggests that the co-delivery of PTX and Cet by ND enhanced the effects of mitotic catastrophe and apoptosis in vitro and in vivo [ 134 ].…”

Section: Types Of Nps Used For Combination Therapymentioning

confidence: 99%

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Gurunathan

Kang

Qasim

et al. 2018

IJMS

271

133

View full text Add to dashboard Cite

Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallic nanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation and leads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatic tumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapies in various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies. Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is less than that of the combination of NPs and anticancer drugs. Combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome. Combination therapy with anticancer drugs has been shown to generally induce synergistic drug actions and deter the onset of drug resistance. Therefore, this review is designed to report and analyze the recent progress made to address combination therapy using NPs and anticancer drugs. We first provide a comprehensive overview of the angiogenesis and of the different types of NPs currently used in treatments of cancer; those emphasized in this review are liposomes, polymeric NPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbon nanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used for combination therapy with various anticancer agents. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology.

show abstract

Section: Types Of Nps Used For Combination Therapymentioning

confidence: 99%

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Gurunathan

Kang

Qasim

et al. 2018

IJMS

271

133

View full text Add to dashboard Cite

show abstract

“…PTX has demonstrated outstanding antitumor activity due to high-affinity binding to microtubules, stabilizing and enhancing tubulin polymerization, and as suppressors of spindle microtubule dynamics (Wang et al., 2016 ; Zhang et al., 2018 ). Subsequently, all those actions contribute to the suppression of cell mitosis, motility and intracellular transport, which lead ultimately to the apoptosis of carcinomas (Lin et al., 2017 ). Due to the above properties, PTX has frequently been employed as a model drug among a number of important chemotherapeutic agents in recent cancer research (Yuan et al., 2015 ).…”

Section: Introductionmentioning

confidence: 99%

l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells

Niu

Bremner

et al. 2018

Drug Delivery

View full text Add to dashboard Cite

Nanoparticles and macromolecular carriers have been widely used to increase the efficacy of chemotherapeutics, largely through passive accumulation provided by their enhanced permeability and retention effect. However, the therapeutic efficacy of nanoscale anticancer drug delivery systems is severely truncated by their low tumor-targetability and inefficient drug release at the target site. Here, the design and development of novel l-peptide functionalized dual-responsive nanoparticles (l-CS-g-PNIPAM-PTX) for active targeting and effective treatment of GRP78-overexpressing human breast cancer in vitro and in vivo are reported. l-CS-g-PNIPAM-PTX NPs have a relative high drug loading (13.5%) and excellent encapsulation efficiency (74.3%) and an average diameter of 275 nm. The release of PTX is slow at pH 7.4 and 25 °C but greatly accelerated at pH 5.0 and 37 °C. MTT assays and confocal experiments showed that the l-CS-g-PNIPAM-PTX NPs possessed high targetability and antitumor activity toward GRP78 overexpressing MDA-MB-231 human breast cancer cells. As expected, l-CS-g-PNIPAM-PTX NPs could effectively treat mice bearing MDA-MB-231 human breast tumor xenografts with little side effects, resulting in complete inhibition of tumor growth and a high survival rate over an experimental period of 60 days. These results indicate that l-peptide-functionalized acid – and thermally activated – PTX prodrug NPs have a great potential for targeted chemotherapy in breast cancer.

show abstract

“…Their major limitation is dose-dependent side effects such as myelosuppression, cardiotoxicity, and the development of acute myeloid leukemia [39] . Many reports have shown that the binding of anthracyclines to the nanodiamond carriers significantly reduced the effective dosage, resulting in lesser side effects [40][41][42][43][44] . The first reports describing transportation of doxorubicin by nanodiamonds used drug physisorption onto nanoparticles.…”

Section: Nanodiamonds As Drug Carriersmentioning

confidence: 99%

Why nanodiamond carriers manage to overcome drug resistance in cancer

Benson¹,

Amini²

2020

CDR

View full text Add to dashboard Cite

Nanodiamonds represent an attractive potential carrier for anticancer drugs. The main advantages of nanodiamond particles with respect to medical applications are their high compatibility with non-cancerous cells, feasible surface decoration with therapeutic and cancer-cell targeting molecules, and their relatively low manufacturing cost. Additionally, nanodiamond carriers significantly increase treatment efficacy of the loaded drug, so anticancer drugs execute more effectively at a lower dose. Subsequently, lower drug dose results in less extensive side effects. The carriers decorated with a targeting molecule accumulate primarily in the tumor tissue, and those nanodiamond particles impair efflux of the drug from cancer cells. Therapeutic approaches considering nanodiamond carriers were already tested in vitro , as well as in vivo. Now, researchers focus particularly on the possible side effects of nanodiamond carriers applied systemically in vivo. The behavior of nanodiamond carriers depends heavily on their surface coatings, so each therapeutic complex must be evaluated separately. Generally, it seems that site-specific application of nanodiamond carriers is a rather safe therapeutic approach, but intravenous application needs further study. The benefits of nanodiamond carriers are remarkable and represent a potent approach to overcome the drug resistance of many cancers.

show abstract

Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition

Cited by 29 publications

References 59 publications

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells

Why nanodiamond carriers manage to overcome drug resistance in cancer

Contact Info

Product

Resources

About